Tag: Performance Objectives

On Thursday, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for AngioDynamics' (NASDAQ: ANGO) AlphaVac F1885 system for the treatment of pulmonary embolism (PE). The expanded FDA indication allows the use of the AlphaVac F1885 System for the treatment of pulmonary embolism, expanding the applicability of the AlphaVac F1885 System for the non-surgical removal of thrombus or embolus from venous blood vessels. The indication expands treatment options for PE patients, reduces thrombus burden, and improves right ventricular function. It also includes